Corient Private Wealth LP Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARE

Corient Private Wealth LP acquired a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 139,094 shares of the biopharmaceutical company’s stock, valued at approximately $4,644,000.

A number of other institutional investors and hedge funds have also modified their holdings of RARE. BlackRock Inc. bought a new position in Ultragenyx Pharmaceutical in the second quarter worth $355,746,000. Vanguard Group Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock valued at $236,068,000 after buying an additional 131,087 shares in the last quarter. State Street Corp raised its stake in shares of Ultragenyx Pharmaceutical by 16.5% in the 4th quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock valued at $98,970,000 after buying an additional 610,559 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Ultragenyx Pharmaceutical by 26.6% during the 4th quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock worth $56,624,000 after acquiring an additional 516,781 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock worth $47,298,000 after acquiring an additional 2,057,951 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the transaction, the director directly owned 21,095 shares in the company, valued at approximately $528,429.75. This represents a 8.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 1.6%

NASDAQ RARE opened at $25.21 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.29 and a 1-year high of $39.89. The company has a 50 day moving average of $28.47 and a 200-day moving average of $25.04. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -4.32 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.32. The business had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.Ultragenyx Pharmaceutical’s revenue was up 28.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.17) EPS. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -3.97 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wedbush lowered their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Morgan Stanley raised their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the stock an “overweight” rating in a research note on Friday, August 21st. Royal Bank Of Canada lifted their price objective on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Wells Fargo & Company upped their price objective on Ultragenyx Pharmaceutical from $46.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Canaccord Genuity Group increased their target price on Ultragenyx Pharmaceutical from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.44.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.